MAS
CRSP icon

Meeder Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Meeder Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Buy
4,646
+380
+9% +$20K 0.01% 621
2026
Q1 		$203K Sell
4,266
-126
-3% -$6.65K 0.01% 655
2025
Q4 		$230K Buy
4,392
+270
+7% +$16.2K 0.01% 601
2025
Q3 		$267K Buy
+4,122
New +$237K 0.01% 516

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Meeder Advisory Services's CRSP Position: Q2 2026 in Review

Meeder Advisory Services increased its CRISPR Therapeutics (CRSP) stake by 8.9% in Q2 2026, buying an estimated $20K and bringing the position to 4,646 shares worth $253K. The position accounts for 0.01% of the portfolio, ranked #621.

Meeder Advisory Services first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. The position peaked at $267K in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Meeder Advisory Services held 4,646 shares of CRISPR Therapeutics worth $253K as of Q2 2026.
  • Meeder Advisory Services bought 380 CRISPR Therapeutics shares in Q2 2026, an estimated $20K.
  • CRISPR Therapeutics made up 0.01% of Meeder Advisory Services's portfolio in Q2 2026, its #621 holding.
  • Meeder Advisory Services first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Meeder Advisory Services's CRISPR Therapeutics position peaked at $267K in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Meeder Advisory Services's 13F filing for Q2 2026, filed 7 Aug 2026.